Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It is an autoimmune disease and may be triggered by smoking, alcohol consumption, cold or dry weather and stress.
In the wake of lesser treatment options and costly therapies, psoriasis remains as an under treated disease. Psoriasis treatment can be divided into three main groups: topical treatment, light therapy, and systemic medication based on the severity of the disease. The typical treatment options include TNF inhibitors and IL inhibitors. However, various therapies and drugs are in the pipeline and it is expected that treatment options will improve over time with higher efficacy and lower costs.
The global market for psoriasis has been increasing consistently over the last few years. The major factors contributing to the growth of the global psoriasis market are increasing smoking and alcohol consumption trends globally. Surging smoking population, increased spending on medicines, increasing sales of prescription drugs and escalating health care expenditure are the key growth drivers of the market. However, growth of the market is hindered by extensive drug development and approval process and side-effects associated with the existing medication for psoriasis.
Various treatment methods are readily used to control psoriasis in the US, such as TNFs, systemics and topicals. With relatively higher prevalence rates in the US, several companies are trying to grab larger market shares with their new and innovative drugs. Plaque psoriasis is a common form of this disease in the US with increasing prevalence each year.
The report “Global Psoriasis Market” analyzes the development of this market, with focus on the US treatment market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Johnson and Johnson, Abbvie inc., Amgen Inc. and Novartis are being profiled along with their key financials and strategies for growth.
In the wake of lesser treatment options and costly therapies, psoriasis remains as an under treated disease. Psoriasis treatment can be divided into three main groups: topical treatment, light therapy, and systemic medication based on the severity of the disease. The typical treatment options include TNF inhibitors and IL inhibitors. However, various therapies and drugs are in the pipeline and it is expected that treatment options will improve over time with higher efficacy and lower costs.
The global market for psoriasis has been increasing consistently over the last few years. The major factors contributing to the growth of the global psoriasis market are increasing smoking and alcohol consumption trends globally. Surging smoking population, increased spending on medicines, increasing sales of prescription drugs and escalating health care expenditure are the key growth drivers of the market. However, growth of the market is hindered by extensive drug development and approval process and side-effects associated with the existing medication for psoriasis.
Various treatment methods are readily used to control psoriasis in the US, such as TNFs, systemics and topicals. With relatively higher prevalence rates in the US, several companies are trying to grab larger market shares with their new and innovative drugs. Plaque psoriasis is a common form of this disease in the US with increasing prevalence each year.
The report “Global Psoriasis Market” analyzes the development of this market, with focus on the US treatment market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Johnson and Johnson, Abbvie inc., Amgen Inc. and Novartis are being profiled along with their key financials and strategies for growth.
1. MARKET OVERVIEW
1.1 Psoriasis
1.2 Types
1.2.1 Plaque Psoriasis
1.2.2 Guttate Psoriasis
1.2.3 Inverse Psoriasis
1.2.4 Pustular Psoriasis
1.2.5 Erytherodermic Psoriasis
1.3 Causes
1.4 Symptoms by Types
1.4.1 Plaque Psoriasis
1.4.2 Guttate Psoriasis
1.4.3 Inverse Psoriasis
1.4.4 Pustular Psoriasis
1.4.5 Erytherodermic Psoriasis
1.5 Diagnosis
1.6 Treatment Options
1.6.1 Topical Treatments
1.6.2 Light Therapy or Phototherapy
1.6.3 Systemic Treatments
2. GLOBAL MARKET
2.1 Global Psoriasis Market by Value
2.2 Global Psoriasis Market by Therapy
3. THE US MARKET
3.1 Autoimmune Disease Market
3.1.1 The US Autoimmune Disease Market by Value
3.2 Psoriasis Market
3.2.1 The US Psoriasis Prevalence
3.2.2 The US Psoriasis Market by Value
3.2.3 The US Psoriasis Market by Treatment
3.2.4 The US Psoriasis IL-Inhibitors Market by Value
3.3 Plaque Psoriasis Market
3.3.1 The US Plaque Psoriasis Prevalence
3.3.2 The US Plaque Psoriasis Patients on Treatment
3.3.2 The US Plaque Psoriasis Biologics Market by Type
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Surging Smoking Population
4.1.2 Increased Spending on Medicines
4.1.3 Increasing Sales of Prescription Drugs
4.1.4 Escalating Healthcare Expenditure
4.2 Key Trends
4.2.1 New Drugs against Psoriasis
4.2.2 Psoriasis Treatment Evolution
4.2.3 Key Pipeline Products in Conventional Therapies
4.2.4 Development of IL Based Treatments
4.2.5 Drug Development for Plaque Psoriasis
4.3 Challenges
4.3.1 Major Side-Effects of New Psoriasis Drugs
4.3.2 Extensive Drug Development and Approval Process
5. COMPETITION
5.1 Global Market
5.1.1 Price Comparison of Key Biologic for Psoriasis
5.2 US Market
5.2.1 The US Psoriasis Biologics Revenue Comparison
5.2.1 The US Revenue Comparison per Patient for Psoriasis Drugs
6. COMPANY PROFILES
6.1 Johnson & Johnson
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Abbvie Inc.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Amgen Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Novartis
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
1.1 Psoriasis
1.2 Types
1.2.1 Plaque Psoriasis
1.2.2 Guttate Psoriasis
1.2.3 Inverse Psoriasis
1.2.4 Pustular Psoriasis
1.2.5 Erytherodermic Psoriasis
1.3 Causes
1.4 Symptoms by Types
1.4.1 Plaque Psoriasis
1.4.2 Guttate Psoriasis
1.4.3 Inverse Psoriasis
1.4.4 Pustular Psoriasis
1.4.5 Erytherodermic Psoriasis
1.5 Diagnosis
1.6 Treatment Options
1.6.1 Topical Treatments
1.6.2 Light Therapy or Phototherapy
1.6.3 Systemic Treatments
2. GLOBAL MARKET
2.1 Global Psoriasis Market by Value
2.2 Global Psoriasis Market by Therapy
3. THE US MARKET
3.1 Autoimmune Disease Market
3.1.1 The US Autoimmune Disease Market by Value
3.2 Psoriasis Market
3.2.1 The US Psoriasis Prevalence
3.2.2 The US Psoriasis Market by Value
3.2.3 The US Psoriasis Market by Treatment
3.2.4 The US Psoriasis IL-Inhibitors Market by Value
3.3 Plaque Psoriasis Market
3.3.1 The US Plaque Psoriasis Prevalence
3.3.2 The US Plaque Psoriasis Patients on Treatment
3.3.2 The US Plaque Psoriasis Biologics Market by Type
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Surging Smoking Population
4.1.2 Increased Spending on Medicines
4.1.3 Increasing Sales of Prescription Drugs
4.1.4 Escalating Healthcare Expenditure
4.2 Key Trends
4.2.1 New Drugs against Psoriasis
4.2.2 Psoriasis Treatment Evolution
4.2.3 Key Pipeline Products in Conventional Therapies
4.2.4 Development of IL Based Treatments
4.2.5 Drug Development for Plaque Psoriasis
4.3 Challenges
4.3.1 Major Side-Effects of New Psoriasis Drugs
4.3.2 Extensive Drug Development and Approval Process
5. COMPETITION
5.1 Global Market
5.1.1 Price Comparison of Key Biologic for Psoriasis
5.2 US Market
5.2.1 The US Psoriasis Biologics Revenue Comparison
5.2.1 The US Revenue Comparison per Patient for Psoriasis Drugs
6. COMPANY PROFILES
6.1 Johnson & Johnson
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Abbvie Inc.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Amgen Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Novartis
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
LIST OF CHARTS
Current Treatment Options for Psoriasis
Global Psoriasis Market by Value (2013-2020E)
Global Psoriasis Market by Therapy (2015)
Global Psoriasis Market by Therapy (2025E)
The US Autoimmune Disease Market by Value (2010-2015)
The US Psoriasis Prevalence (2016E-2020E)
The US Psoriasis Market by Value (2010-2015)
The US Psoriasis Market Forecast by Value (2016E-2020E)
The US Psoriasis Market by Treatment (2015)
The US Psoriasis Market by IL Inhibitors (2016E-2020E)
The US Plaque Psoriasis Prevalence (2016E-2020E)
The US Plaque Psoriasis Patients On Treatment (2016E-2020E)
The US Plaque Psoriasis Biologics Market by Type (2015)
Global Cigarette Consumption (1910-2014)
Global Spending on Medicines (2010-2020E)
Global Per Capita Healthcare Expenditure (2006-2015E)
Global Sales of Prescription Drugs (2010-2015E)
The US Annual Revenue Per Patient for Psoriasis Drugs (2015)
Johnson and Johnson’s Revenue Share by Segment (2015)
Johnson and Johnson’s Revenue and Net Income (2011-2015)
Abbvie’s Revenue Share by Products (2015)
Abbvie Revenue and Net Income (2011-2015)
Abbvie’s Research & Development Expenditure (2013-2015)
Amgen’s Revenue Share by Products (2015)
Amgen Inc. Revenue and Net Income (2012-2015)
Amgen’s R&D Expenditure (2012-2015)
Novartis Revenue Share by Segments (2015)
Novartis Revenue and Net Income (2012-2015)
Current Treatment Options for Psoriasis
Global Psoriasis Market by Value (2013-2020E)
Global Psoriasis Market by Therapy (2015)
Global Psoriasis Market by Therapy (2025E)
The US Autoimmune Disease Market by Value (2010-2015)
The US Psoriasis Prevalence (2016E-2020E)
The US Psoriasis Market by Value (2010-2015)
The US Psoriasis Market Forecast by Value (2016E-2020E)
The US Psoriasis Market by Treatment (2015)
The US Psoriasis Market by IL Inhibitors (2016E-2020E)
The US Plaque Psoriasis Prevalence (2016E-2020E)
The US Plaque Psoriasis Patients On Treatment (2016E-2020E)
The US Plaque Psoriasis Biologics Market by Type (2015)
Global Cigarette Consumption (1910-2014)
Global Spending on Medicines (2010-2020E)
Global Per Capita Healthcare Expenditure (2006-2015E)
Global Sales of Prescription Drugs (2010-2015E)
The US Annual Revenue Per Patient for Psoriasis Drugs (2015)
Johnson and Johnson’s Revenue Share by Segment (2015)
Johnson and Johnson’s Revenue and Net Income (2011-2015)
Abbvie’s Revenue Share by Products (2015)
Abbvie Revenue and Net Income (2011-2015)
Abbvie’s Research & Development Expenditure (2013-2015)
Amgen’s Revenue Share by Products (2015)
Amgen Inc. Revenue and Net Income (2012-2015)
Amgen’s R&D Expenditure (2012-2015)
Novartis Revenue Share by Segments (2015)
Novartis Revenue and Net Income (2012-2015)
LIST OF TABLES
Status of New Drugs against Psoriasis
Key Pipeline Products in Conventional Therapies (2015)
Key IL-Based Treatments in Development
Major Side Effects of New Psoriasis Drugs
Price Comparison of Key Biologics (2015)
Biologics Treatment by Revenue (2015)
J&J Research and Development Expenditure by Segments (2014-2015)
Status of New Drugs against Psoriasis
Key Pipeline Products in Conventional Therapies (2015)
Key IL-Based Treatments in Development
Major Side Effects of New Psoriasis Drugs
Price Comparison of Key Biologics (2015)
Biologics Treatment by Revenue (2015)
J&J Research and Development Expenditure by Segments (2014-2015)
